In vivo role of NAD(P)H:quinone oxidoreductase 1 in metabolic activation of mitomycin C and bone marrow cytotoxicity

Cancer Research

Volumn 67, Issue 17, 2007, Pages 7966-7971

  Adikesavan, Anbu Karani ^a   Barrios, Roberto ^b   Jaiswal, Anil K ^a,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAVOPROTEIN; HEMOGLOBIN; MITOMYCIN C; NAD(P)H:QUINONE OXIDOREDUCTASE 1; NRH:QUINONE OXIDOREDUCTASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

ADIPOCYTE; ANEMIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CELL; BLOOD CELL COUNT; BONE MARROW; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG METABOLISM; ERYTHROCYTE; FEMALE; GENE FUNCTION; HISTOLOGY; IN VIVO STUDY; MALE; METABOLIC ACTIVATION; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE; WILD TYPE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BIOTRANSFORMATION; BONE MARROW CELLS; ERYTHROCYTE COUNT; FEMALE; HEMOGLOBINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOMYCIN; NADPH DEHYDROGENASE;

EID: 34548565804     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4480     Document Type: Article

References (20)

1. Ross D, Beall HD, Siegel D, Traver RD, Gustafson DL. Enzymology of bioreductive drug activation. Br J Cancer Suppl 1996;27:S1-8.
2. Workman P. Enzyme-directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase. Oncol Res 1994;6:461-75.
3. Fourie J, Oleschuk CJ, Guziec F, Jr., et al. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT diaphorase. Cancer Chemother Pharmacol 2002;49:101-10.
4. Verweij J, Pinedo HH. Mitomycin C. In: Pinedo HM, Cabner BA, Longo DL, editors. Cancer chemotherapy and biological modifiers. Annual 11. Amsterdam: Elsevier Science Publishers; 1990. p. 63-73.
5. Iyer VN, Szybalski W. Mitomycins and porfiromycin: chemical mechanism of activation and cross-linking of DNA. Science 1964;145:55-8.
6. Belinsky M, Jaiswal AK. NAD(P)H:quinone oxidoreductase1 (DT diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev 1993;12:103-17.
7. Dulhanty AM, Whitmore GF. Chinese hamster ovary cells resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase. Cancer Res 1991;51:1860-5.
8. Wang X, Doherty GP, Leith MK, Curphey TJ, Begleiter A. Enhanced cytotoxicity of mitomycin C in human tumor cells with inducers of DT diaphorase. Br J Cancer 1999;80:1223-30.
9. Powis G, Gasdaska PY, Gallegos A, Sherrill K, Goodman D. Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs. Anticancer Res 1995;15:1141-6.
10. Plumb JA, Workman P. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT diaphorase activity. Int J Cancer 1994;56:134-9.
11. Knox RJ, Jenkins TC, Hobbs SM, Chen S, Melton RG, Burke PJ. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy. Cancer Res 2000;60:4179-86.
12. Celli CM, Tran N, Knox R, Jaiswal AK. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs. Biochem Pharmacol 2006;72:366-76.
13. Joseph P, Xie T, Xu YH, Jaiswal AK. NAD(P)H:quinone oxidoreductase(1) (DT-diaphorase): expression, regulation, and role in cancer. Oncol Res 1994;6:525-32.
14. Schlager JJ, Powis G. Mitomycin C is not metabolized by but is an inhibitor of human kidney NAD(P)H:(quinone acceptor) oxidoreductase. Cancer Chemother Pharmacol 1988;22:126-30.
15. Cresteil T, Jaiswal AK. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumor cells compared to normal cells of the same origin. Biochem Pharm 1991;42:1021-7.
16. Rajendirane V, Joseph P, Lee Y, et al. Disruption of the DT diaphorase (NQO1) in mice leads to increased menadione toxicity. J Biol Chem 1998;273:7382-9.
17. Long II DJ, Iskander K, Gaikwad A, et al. Disruption of dihydronicotinamide riboside:quinone oxidoreductase2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J Biol Chem 2002;277:46131-9.
18. Pan SS, Andrews PA, Glover CJ. Reductive activation of mitomycin C metabolites catalyzed by NADPH-cytochrome P450 reductase and xanthine oxidase. J Biol Chem 1984;259:959-66.
19. Takeiri A, Mishima M, Tanaka K, et al. Molecular characterization of mitomycin C-induced large deletions and tandem-base substitutions in the bone marrow of gpt delta transgenic mice. Chem Res Toxicol 2003;16:171-9.
20. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol 2001;59:263-8.